Phase 3 data suggest PSMA-PET-CT could reduce unnecessary prostate biopsies in selected high-risk men, though longer ...

Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage. Project History with links to source of information ...

In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with 18 F-DCFPyL PSMA PET/CT has been shown to considerably improve detection of active disease as ...

Patients with metastatic castration-resistant prostate cancer treated with radioligand therapy, a form of targeted therapy, had improvements in PSA levels and survival with favorable side effect ...

Prostate cancer cells have high levels of prostate-specific membrane antigen (PSMA), but researchers were unsure of its biological role. Now an MSK-led team has discovered that PSMA contributes to ...

A new UCLA Health Jonsson Comprehensive Cancer Center-led study has revealed that advanced prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging could reveal metastatic ...

Figure 1. Time to castration-resistant prostate cancer (CRPC) by PSMA PET/CT bone lesion cohort at initial staging. Kaplan Meier curves showing time to CRPC by bone lesion cohort on PSMA PET/CT at ...

A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen ...

PSMA-PET quantification required labor-intensive semiautomated software not in routine use. The study enrolled a high-risk metastatic castration-resistant prostate cancer subgroup, limiting ...

In men recently diagnosed with intermediate or high-grade prostate cancer, prostate specific membrane antigen (PSMA) PET/MRI can successfully determine whether their cancer is likely to return within ...